Hepatocellular carcinoma Trials in Nanjing, China
Conditions / Hepatocellular carcinoma / Nanjing, China
Hepatocellular carcinoma is a medical condition with active clinical research programs worldwide.
62 total trials for this combination
Showing top 10 of 62 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | UNKNOWN | PHASE1 |
| NCT03778957 | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | — |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | TERMINATED | PHASE1/PHASE2 |
| NCT03778957 | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | — |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | COMPLETED | PHASE4 |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | RECRUITING | PHASE3 |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | PHASE3 |